Terumo Corporation · TSE:4543
Terumo — Investor Presentation (November 2018)
14 slides from Terumo's investor presentation, Nov 8, 2018
Slide 1: Growth Strategy in Japan
Growth Strategy in Japan Terumo Corporation President and CEO Shinjiro Sato November 8, 2018
Slide 2: Mid- to Long-term Growth Strategy Progressing Steadily
Mid‐ to Long‐term Growth Strategy Progressing Steadily Launched Ultimaster Tansei in JP,EU, and Aisa Select growing segments and segments where Win in Made an agreement on acquisition of Terumo owns a competitive advantage Selected Chinese DES company Interventional systems, neurovascular, allia
Slide 3: Revenue Growth in Japan for The Past Ten Years
Revenue Growth in Japan for The Past Ten Years Nearly flat since FY2011 Trend of Revenue in Japan (Terumo) (billion yen) 200.0 150.0 100.0 50.0 0.0 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 © Terumo Corporation 2018/11/8 2/13
Slide 4: Japan Is The Biggest Market for Terumo Where Its Business Is General Hospital Centric
Japan Is The Biggest Market for Terumo Where Its Business Is General Hospital Centric FY17 Revenue by region FY17 Revenue by business Blood Manage‐ Asia Japan ment 6% 19% 32% Cardiac and Vascular 28% Revenue % Revenue % Europe by region in Japan 20% General Americas Hospital 29% 65% © Terumo Corpora
Slide 5: Profitability of General Hospital Has Recovered
Profitability of General Hospital Has Recovered Adjusted operating margin for General Hospital Company 20% 15% 10% 5% 0% FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 Great timing for the company to refocus on its growth in JP © Terumo Corporation 2018/11/8 4/13
Slide 6: Deploy Large-scale Products in Each Business Arena
Deploy Large‐scale Products in Each Business Arena Utilize all assets incl. products, sales infrastructure, and corporate functions Lead the industry with differentiated products Provide solutions to new needs at the medical front Introduce successful outcomes of acquisition as well as overseas R&D
Slide 7: Utilize Digital Health in Intensive Care
Differentiated products Utilize Digital Health in Intensive Care Solution to new needs Lever OJP M&A and R&D External techs and B2B Sell Japan's only prescription‐linked pump Promote further medical safety and workflow efficiency through automated setup for administration ICU management Anesthesia
Slide 8: Entry into Therapeutic Arena of Diabetes Management
Differentiated products Solution to new needs Entry into Therapeutic Arena of Diabetes Management Lever OJP M&A and R&D External techs and B2B Own lineups of three types of devices, SMBG, CGM, and insulin pump Continuous Glucose Monitoring Insulin pump (CGM) Blood glucose alert function Japan's fir
Slide 9: Provide Pharmaceutical Solutions
Differentiated products Solution to new needs Provide Pharmaceutical Solutions Lever OJP M&A and R&D External techs and B2B Pain managemant Drug and Device Enhance product lineup by adding Fentanyl injection Acelio I.V. solution is the only such product in Japan Offer multimodal analgesia with Desig
Slide 10: Expand Therapeutic Devices for Intervention
Differentiated products Solution to new needs Expand Therapeutic Devices for Intervention Lever OJP M&A and R&D External techs and B2B Therapeutic devices for Therapeutic devices coronary intervention for neurovascular intervention Drug‐eluting stent PTCA balloon Upgraded delivery performance Full l
Slide 11: Seek for Less Invasive Treatment in the Area of Surgery
Differentiated products Solution to new needs Seek for Less Invasive Treatment in the Area of Surgery Lever OJP M&A and R&D External techs and B2B Stent graft for thoracic aortic Oxygenator aneurysm CAPIOX NX Reduced priming volume by 30% Precise deployment w/ superior Adult oxygenator w/ world's lo
Slide 12: Expand from Blood Center Business to Therapeutic Apheresis and Cell Therapy
Differentiated products Expand from Blood Center Business to Therapeutic Apheresis Solution to new needs and Cell Therapy Lever OJP M&A and R&D External techs and B2B Hematopoietic stem cell transplant Regenerative medicine systems UV treatment Make the de facto standard of production Chronic GVHD*
Slide 13: To Fully Utilize Overall Distinctive Strength in Japan
To Fully Utilize Overall Distinctive Strength in Japan Strategically promote projects through “Scrum 2018” 1 Promote collaborative sales approaches across the businesses 2 Appeal for Terumo brand 3 Enhance corporate infrastructure (Regulatory affairs, etc.) 4 Commence disease‐oriented approach (Can
Slide 14: IR Contact
IR Contact Terumo Corporation Corporate Communication (IR) Dept. E‐mail: [email protected] Among the information that Terumo discloses, the forward‐looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i